Stocks · News reference

8-K filing — ADC Therapeutics SA (ADCT)

Oct 13, 2026, 10:26 AMSEC EDGAR

Filed: 2026-10-13 AccNo: 0000950103-26-015465 Size: 808 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ADCT

Source: edgar
Observed: Oct 13, 2026, 10:26 AM
Checked: Oct 13, 2026, 10:26 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 8, 2026, 1:07 PMBenzinga Newsdesk
ADC Therapeutics Announces $86.6M Pipe Financing For 12.9M Shares At $1.42/Share And Warrants To Purchase 48.1M Shares At $1.32/Warrant; Secures Loan And Royalty Amendments
ADCT
BenzingaAug 17, 2026, 1:41 PMBenzinga Newsdesk
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.
ADCT
BenzingaAug 13, 2026, 6:14 PMBenzinga Newsdesk
ADC Therapeutics shares are trading lower after the company reported mixed Q2 financial results.
ADCT

8-K filing — ADC Therapeutics SA (ADCT)

Connected Markets

Related Headlines

ADC Therapeutics Announces $86.6M Pipe Financing For 12.9M Shares At $1.42/Share And Warrants To Purchase 48.1M Shares At $1.32/Warrant; Secures Loan And Royalty Amendments

Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

ADC Therapeutics shares are trading lower after the company reported mixed Q2 financial results.